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ABSTRACT 
It has been well documented that ascorbate enhances iron uptake, with a proposed mechanism 
based on reduction to the more absorbable ferrous form.  We have performed a study on the 
effects of ascorbate on ferric iron uptake in the human epithelial Caco-2 cell-line. Ascorbate 
increased uptake in a concentration-dependent manner with a significant difference between iron 
uptake and reduction.  Uptake kinetics are characteristic of a non-essential activator and the 
formation of an Fe
3+
-ascorbate complex.  This investigation provides evidence that ascorbate 
enhances the apical uptake of ferric iron into Caco-2 cells through the formation of a Fe
3+
-
ascorbate complex.  
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1. Introduction 
An adequate dietary supply of iron is essential both to maintain red blood cell production 
and for the normal function of a number of key metabolic enzymes.  Body iron is maintained 
primarily by regulation of the absorption of dietary iron in the proximal small intestine (Sharp,  
Tandy, Yamaji, Tennant, Williams & Singh Srai, 2002; Sharp & Srai, 2007).  Dietary iron is 
found in two basic forms, as haem or non-haem, in the form of iron oxides, salts or chelates.  
Non-haem iron is the predominant form in most diets, but the bioavailability of this form is 
relatively low (1-10%) (Sharp & Srai, 2007).  The uptake of dietary non-haem iron into the 
gastrointestinal (GI) tract requires protein-mediated transport, and two separate enterocyte 
pathways have been identified, namely the Divalent Metal Transporter-1 (DMT1) and the 
Integrin-Mobilferrin pathway (IMP) (Conrad & Umbreit, 2000; Conrad et al., 2000).  DMT1 
requires the iron to be in the ferrous form (Fe
2+
), and as a major proportion of dietary iron is in 
the ferric form (Fe
3+
) it needs to be reduced prior to uptake by DMT1 in the enterocytes.  Several 
mechanisms are potentially available to reduce non-haem iron into the ferrous form.  The brush 
border of duodenal enterocytes and cultured intestinal cells possess ferric reductase enzyme 
activity (Dcytb) (Latunde-Dada,  Van der Westhuizen,  Vulpe,  Anderson, Simpson & Mckie, 
2002), and overexpression of Dcytb in intestinal cells has been shown to stimulate iron uptake 
(Latunde-Dada, Simpson & Mckie, 2008).  Non-haem iron can also be reduced by dietary factors, 
the most important being ascorbate that can reduce ferric iron to the more absorbable ferrous 
form (Teucher, Olivares & Cori, 2004).  The presence of ascorbate has been previously shown to 
increase iron uptake in a dose-dependent fashion in vitro (Han, Failla, Hill, Morris & Smith, 
1995; Kalgaonkar & Lonnerdal, 2008) and to increase the absorption of iron in human studies 
(Olivares, Pizarro, Pineda, Name, Hertrampf & Walter, 1997; Lopez & Martos, 2004; Moretti, 
Zimmermann, Wegmuller, Walczyk, Zeder & Hurrell, 2006).  Following reduction, the Fe
2+
 
becomes a substrate for DMT1 (Sharp & Srai, 2007).  In contrast to DMT1, the IMP pathway 
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transports solely ferric iron, but not other metals of nutritional importance, and requires the 
chelation of ferric iron by mucins before interaction with 3-integrin and mobilferrin (Conrad & 
Umbreit, 2002; Sharp & Srai, 2007).    
The purpose of this study was to gain a better understanding of the mechanism by which 
ascorbate enhances the uptake of ferric iron into the small intestine, using the Caco-2 cell model 
of human small intestinal enterocytes (Yamaji, Tennant, Tandy, Williams, Singh Srai & Sharp, 
2001).  We have used a kinetic approach and interpreted the results to show that ferric iron forms 
a complex with ascorbate, which is subsequently transported into the cells by a DMT1-
independent mechanism.   
 
 
2. Materials and methods 
 
2.1. Cell culture 
Caco-2 TC7 cells were maintained in 25-cm
2
 plastic flasks.  The cells were grown in Dulbecco’s 
Modified Eagle Medium (DMEM) from GIBCO (Grand Island, NY), supplemented with 20% 
v/v foetal calf serum (GIBCO), 1% v/v non-essential amino acids (GIBCO), 1% antibiotic 
antimycotic (penicillin-steptomycin) solution (GIBCO) and 1% v/v L-glutamine (Biowhittaker 
Europe; Verviers, Belgium).  The cells were maintained at 37 ºC in an incubator with 5% carbon 
dioxide (CO2), 95% air atmosphere at constant 95% relative humidity, and the medium replaced 
every 2 days.  For iron uptake experiments, the cells were seeded at a density of 40,000 cells/cm
2
 
in collagen-treated six-well plates (Costar Corp.; Cambridge, MA) and used at 21 days after 
seeding (Johnson, Yamaji, Tennant, Srai & Sharp, 2005). 
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2.2. Iron uptake studies  
Caco-2 cells were transferred to serum-free medium for 24 hours before the start of experiments.  
The cells were washed by incubation with buffer (140 mM NaCl, 5 mM KCl, 1 mM NaH2PO4, 
10 mM MES, 0.5 mM of MgCl2, 1 mM CaCl2 pH 6.0) for 2 minutes at 37 ºC.  In order to 
measure iron uptake, 60 kBq of 
55
Fe(II) were added to each culture well and incubated for 15 
minutes at 37 ºC.  Uptake was stopped by washing the cells three times with ice-cold buffer and 
the cells were solubilised in 1 ml of 200 mM NaOH overnight (4 ºC).  Intracellular radioactivity 
was determined by scintillation counting. 
The data was fitted to a hyperbolic equation by non-linear regression (SigmaPlot, Systat 
Software Inc. San Jose): 
Uptake = Vmax × [FeCl3]/(Km + [FeCl3]) 
where [FeCl3] is the concentration of substrate, Vmax is the calculated maximum velocity of the 
reaction and Km is the calculated Michaelis constant, an indicator of substrate affinity (Segel, 
1975). 
 
2.3. Cell viability assay  
To ensure that our iron and ascorbate treatments did not induce cytotoxicity which might in turn 
influence iron reduction and uptake, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was used to determine cell viability.  This assay measures 
the cleavage of MTT to a formazan derivative by mitochondrial enzymes and there is a linear 
relationship between the amount of formazan produced and the number of viable cells 
(Mosmann, 1983; Ferrari, Fornasiero & Isetta, 1990).  To each well of a 96-well culture plate 
was added 10 µl MTT reagent and the plate was incubated for 3-4 hours (37 ºC), before the 
addition of 100 µl DMSO per well to solubilise the cells.  The absorbance of formazan product 
was determined at 570 nm.  
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2.4. Ferric reduction assay 
The conversion of Fe
3+
 to Fe
2+
 in the absence or presence of ascorbate was measured 
spectrophotometrically by using a chromogenic ferrous iron chelator 
(bathophenanthrolinedisulfonic acid, BPDS) (Timmerman & Woods, 1999).  Uptake buffer (700 
µl) containing various concentrations of Fe
3+
 (0-30 µM) was added to a cell culture well 
containing 21-day post-confluence Caco-2 cultures and incubated for 15 minutes (37 ºC).  The 
buffer was collected (4 ºC) and 500 µl of 2 mM BPDS added before incubation for 1 hour at 37 
ºC.  The concentration of Fe(II)-BPDS complex was measured at 534 nm, using a FeCl2 standard 
curve.  
 
2.5. Statistics and data analysis 
Kinetic parameters were determined by fitting the data to a hyperbolic curve by non-linear 
regression (Prism 5 for Windows, GraphPad Software Inc.).  Two-way ANOVA with Bonferroni 
post-test was used to determine statistical significance (Prism 5 for Windows, GraphPad 
Software Inc.). 
 
 
3. Results and Discussion 
The aim of this study was to kinetically investigate the uptake of non-haem iron by Caco-
2 cells, and its promotion by ascorbate.  The uptake of FeCl3 across the apical membrane of 
Caco-2 cells has been well-documented to be a protein-mediated process, with several proteins 
capable of playing the role of iron transporter (Garrick et al., 2006).  This observation was 
confirmed by the saturable, hyperbolic nature of 
55
Fe(II) uptake (Fig. 1), with a calculated Vmax 
of 304 pmol/h and Km of 13.2 µM.  A previous study showed that ferrous iron uptake by Caco-2 
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cells was also saturable, with a Km of 7 µM (Linder, Moriya, Whon, Kassa & Gilley, 2006), a 
value that is essentially identical to that obtained in our study (Fig. 1).  It has previously been 
shown that the reduction of ferric iron is required for uptake into Caco-2 cells (Han et al., 1995), 
and a potent enhancer of iron uptake is ascorbate (vitamin C) (Teucher, Olivares & Cori, 2004), 
which is capable of reducing ferric to ferrous iron (Johnson, Yamaji, Tennant, Srai & Sharp, 
2005).  In our studies the presence of ascorbate in the cell culture media significantly increased 
the rate of iron uptake in a concentration-dependent manner (Fig. 2; Table 1), and had no effect 
on cell viability at concentrations up to 30 µM ascorbate (data not shown).   
The process by which ascorbate increases iron uptake has previously been ascribed to the 
reductive properties of ascorbate that increase the conversion of ferric to ferrous iron (Teucher et 
al., 2004), the latter then being a substrate for the membrane transporter DMT1 that is specific 
for ferrous iron (Sharp et al., 2002; Sharp & Srai, 2007).  Indeed, it is believed that ascorbate 
secreted in gastric juice is present to reduce dietary iron, preventing the formation of non-
bioavailable ferric chelates (Atanasov, Li, Bjarnason, Tzatchev & Simpson, 2005).  If the 
reduction of ferric iron by ascorbate, or any other dietary reductant, was obligatory for the 
intestinal uptake of dietary ferric iron, then we should not observe a protein-mediated ferric iron 
uptake process.  As shown here (Figs. 1 and 2) and in other studies (Han et al., 1995), this is 
clearly not the case, as the Caco-2 cells take up a low, basal level of iron in the absence of 
ascorbate.  One proposed mechanism to explain this observation involves the presence of a 
membrane-bound ferric reductase, Dcytb, that can catalyse the reduction of ferric iron in the 
absence of ascorbate, or other dietary reducing agents, to stimulate iron reduction and uptake 
into Caco-2 cells (Yamaji et al., 2001; Latunde-Dada et al., 2002; Sharp & Srai, 2007; Latunde-
Dada et al., 2008).  However, the endogenous expression of Dcytb in Caco-2 cells is very low 
(Latunde-Dada et al., 2008). 
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An alternative proposal is that ferric iron reduction is not essential and that there are 
separate pathways for the uptake of ferric and ferrous iron (Han et al., 1995).  In order to 
separate the processes of reduction and increased uptake, both of which could potentially be 
catalysed by ascorbate, we determined ferric iron uptake rates and reduction under identical 
conditions (Fig. 3).  Both iron uptake (Fig. 3A) and ferric iron reduction (Fig. 3B) were 
significantly increased in the presence of ascorbate.  We surmised that if the promoting effect of 
ascorbate on iron uptake was due only to its role as a reductant, then a comparison of 
55
Fe uptake 
vs. ferrous reduction should show a direct, linear correlation with a slope equal to one.  This was 
observed in the absence of ascorbate, but there was a significant difference in the presence of 
ascorbate (Fig. 3C).  This observation implies that a process distinct from iron reduction may 
explain the promoting effect of ascorbate and therefore a kinetic approach was used to determine 
the mechanism of rate enhancement observed with ascorbate.   
Plots of 
55
Fe uptake rates (1/v vs. 1/[
55
Fe]) in the presence of ascorbate display mixed-
type activation kinetics (Fig. 4) (Segel, 1975), with activation of 
55
Fe uptake by ascorbate being 
saturable, as indicated by the finite Vmax obtained (Fig. 4 inset).  These observations are 
characteristic of a non-essential activator process (Segel, 1975) and indicate that ascorbate forms 
a complex with ferric iron that is then taken up into the Caco-2 cells.  This finding implies that 
ascorbate functions as a chelating agent of ferric iron and suggests that an iron-ascorbate 
complex enters the cells directly, although we cannot determine whether the iron in this complex 
is in the Fe
3+
 or Fe
2+ 
form.   
To further explore the kinetics of ascorbate-induced iron uptake we undertook similar 
experiments in the presence of a known inhibitor.  Previous studies have shown that Zn
2+
 inhibits 
the intestinal uptake of iron (Yamaji et al., 2001; Han et al., 1995; Solomons, Pineda, Viteri & 
Sandstead, 1983; Arredondo,  Martinez, Nunez, Ruz & Olivares, 2006; Conrad, Umbreit, Moore, 
Uzel & Berry, 1994), but its effects are not mediated through DMT1 (Tandy et al., 2000; Garrick 
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et al., 2003; Mackenzie, Takanaga, Hubert, Rolfs & Hediger, 2007).  We thus investigated the 
inhibitory effect of Zn
2+ 
on ferric iron
 
uptake into Caco-2 cells, both in the absence and presence 
of ascorbate.  The results showed mixed-type (non-competitive) inhibition of iron uptake (Fig. 5), 
with calculated Ki values of 141 and 236 µM Zn
2+
, in the absence and presence of ascorbate, 
respectively.  The similarity of the inhibition constants (Ki) is interpreted to indicate that the 
same protein complex is involved in ferric iron uptake across the apical membrane of Caco-2 
cells.  As there is an unidentified transporter pathway for iron and zinc in Caco-2 cells that is not 
DMT1 (Yamaji et al., 2001) and DMT1 is specific for ferrous iron (Alonso-Vale et al., 2008), 
our findings would imply that DMT1 is not involved in the uptake of the iron-ascorbate complex.  
Thus, a different transporter system must be involved in the uptake of the iron-ascorbate 
complex and one possibility is that this complex interacts with IMP- 3-intergrin-mobilferrin 
pathway, in a manner similar to that of Fe
3+
-mucin transport complex (Sharp & Srai, 2007), 
while other options include Zip14, a transporter of both iron and zinc in the duodenum, and the 
SVCT1 ascorbate transporter (Liuzzi, Aydemir, Nam, Knutson & Cousins, 2006; Wilson, 2005).   
In conclusion, this investigation provides evidence that ascorbate, in addition to its well-
characterised reduction of ferric iron to provide a bioavailable supply of ferrous iron to DMT1, 
also enhances directly the uptake of ferric iron into Caco-2 cells through the formation of an 
iron-ascorbate complex.  DMT1 is not involved in the uptake of the iron-ascorbate complex and 
further work is required to identify the transporter system involved in the uptake of the iron-
ascorbate complex into intestinal enterocytes. 
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Figure legends: 
 
Figure 1:  Uptake of 
55
Fe into Caco-2 cells in the absence of ascorbate is saturable and 
displays hyperbolic kinetics.  The data were fitted (solid line) to a hyperbolic equation: rate of 
Fe
3+ 
uptake (v) = [S] × Vmax/(Km + [S]), where [S] is the concentration of FeCl3 substrate, Vmax is 
the calculated maximum rate of 
55
Fe uptake and Km is the calculated Michaelis constant at every 
ascorbate concentration.  The calculated Vmax and Km values were 304 ± 18 pmol/h and 13.2 ± 
1.6 µM, respectively  
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Figure 2:  Uptake of 
55
Fe into Caco-2 cells is increased by the presence of ascorbate at 
concentrations of 0 (), 0.5 (▲), 1.0 (), 5.0 (▼) and 10.0 () M ascorbate.  The data were 
fitted separately for every ascorbate concentration to a hyperbolic equation: rate of Fe
3+ 
uptake 
(v) = [S] × Vmax/(Km + [S]), where [S] is the concentration of FeCl3 substrate, Vmax (pmol/h) is the 
calculated maximum rate of 
55
Fe uptake and Km ( M) is the calculated Michaelis constant at 
every ascorbate concentration.  r
2
 > 0.985 for all fitted data. 
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Figure 3:  Effect of ascorbate on the uptake of 
55
Fe or the reduction of Fe
2+
 to Fe
3+
 into Caco-2 
cells.  (A) Uptake of 
55
Fe (, ) and (B) reduction of Fe2+ to Fe3+ (, ●) was measured in the 
presence (, ) or absence of 10 µM ascorbate (, ●).  Data were analysed by two-way 
ANOVA: ***, p < 0.001; ** p < 0.01 for comparison of relevant data sets at each time point.  
(C) Comparison FeCl3 uptake vs. ferrous formation in the presence (●) and absence () of 10 
M ascorbate.  Linear regression analysis indicates a significant difference between the slopes (P 
 0.01), with values of 0.75 ± 0.03 (r2 0.99) and 1.03 ± 0.09 (r2 0.97) in the presence and absence 
of ascorbate. 
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Figure 4:  Effect of ascorbate on the uptake of 
55
Fe into Caco-2 cells. Data from the same 
experiment as in Figure 1 are plotted as 1/v vs. [ascorbate]), at 0 (), 1 ( ), 2 (), and 30 () 
M FeCl3.  The data were fitted to a hyperbolic equation (v = [S] × Vmax/(Km + [S]), as indicated 
by the solid lines.  The insert shows a plot of 1/Vmax vs. [ascorbate], with Vmax determined by 
fitting of the experimental data to the hyperbolic equation. 
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Figure 5:  Effect of zinc on 
55
Fe uptake into Caco-2 cells in the (A) presence or (B) absence of 
ascorbate. Zinc concentrations were 0 (), 100 () and 200 (Δ) µM in the presence of ascorbate, 
and 0 (), 100 () and 200 (▲) µM in the absence of ascorbate.  The data was fitted to a 
hyperbolic equation, as indicated by the solid lines.  (C) A replot of the calculated Km/Vmax ratio 
vs. zinc concentration in the presence ( ) or absence () of 10 µM ascorbate. The data were 
fitted by linear regression, as indicated by the solid lines. 
 
 
ACCEPTED MANUSCRIPT 
19 
Table 1: Kinetic parameters for 
55
Fe uptake into Caco-2 cells in the presence of 0, 0.5, 1.0, 5.0 
and 10.0 M ascorbate.   
 
[Ascorbate] ( M)  Km ( M)  Vmax (pmol/h) 
 
0   13.2 ± 1.6  304 ± 18 
0.5   6.4 ± 1.0  1242 ± 75 
1.0   7.1 ± 0.8  1546 ± 77 
5.0   7.4 ± 0.9  1820 ± 91 
10.0   7.3 ± 1.1  2044 ± 123 
 
The data were fitted separately for every ascorbate concentration to a hyperbolic equation: rate 
of Fe
3+ 
uptake (v) = [S] × Vmax/(Km + [S]), where [S] is the concentration of FeCl3 substrate, Vmax 
(pmol/h) is the calculated maximum rate of 
55
Fe uptake and Km ( M) is the calculated Michaelis 
constant at every ascorbate concentration.  r
2
 > 0.985 for all fitted data. Two-way ANOVA 
indicated a significant effect of ascorbate concentration on Km and Vmax (p < 0.001). 
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